Abstract

Herbal medicines in treatment of cancer as complementary and alternative therapy are accepted increasingly with growing scientific evidences of biomedical research and clinical trials. Anticancer drugs discovered from herbal medicines have a long history and some of them have been used in clinical setting as the conventional anticancer drugs. Actually, herbal medicines are a source for anticancer drug discovery and drug development. Recently, research continuously focuses on clues from traditional use of herbal medicines to develop new anticancer drugs in single pure compounds. On the other hand, standardized various extracts or fractions with anticancer effects or with adjuvant therapy in cancer treatment coming from single or mixed herbs are also accepted forms as dietary supplements and botanical drug products in the US for current statutory regulations. In the present paper, we analyzed the patented agents in the US from herbal medicines in recent ten years, both as potential anticancer extracts/fractions (containing multi-components) and single pure compound(s) that act as new anticancer substances. This review also highlighted the advances in knowledge about quality control, safety, efficacy and recent progress in anticancer candidates in patents of botanical drug products from herbal medicines.

Keywords: Anticancer drugs, antimetastasis drugs, complementary and alternative medicines, Chinese medicines, herbal medicine, patent, vinblastine, vincristine, the camp-tothecin derivatives, topotecan, irinotecan, etoposide, Catharanthus roseus, Don. (Apocynaceae), Camptotheca acuminata Decne (Nys-saceae), Podophyllum peltatum, Taxus brevifolia Nutt. (Taxaceae), Kampo medicine, Ayurveda, Coptidis rhizoma aqueous extract (CRAE), saponins, stelleramacrin A, purified stellera-macrin B, C-2 epimeric xanthones, angeloyl-substituted ingenane, 39-desmethoxyrapamycin, saururus chinensis baill, isoindigo, indigo, indirubin, Scutellaria flavonoid, Panax genus plant, Panax notoginseng solution